HYFC TECHNOLOGY
Genexine, Inc.
The mark consists of a stylized design consisting of two ovals connected by 5 lines to two more ovals that are divided, and are stacked above two other ovals. To the right of the stylized design are the letters "hyFc" stacked above the word "technology".
Mark For: HYFC TECHNOLOGY® trademark registration is intended to cover the categories of
>Color is not claimed as a feature of the mark. The mark consists of a stylized design consisting of two ovals connected by 5 lines to two more ovals that are divided, and are stacked above two other ovals. To the right of the stylized design are the letters "hyFc" stacked above the word "technology".
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79232578 |
| Registration Number | 5736165 |
| Mark Literal Elements | HYFC TECHNOLOGY |
| Mark Drawing Type | 3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S) |
| Mark Type | TRADEMARK |
| Standard Character Claim | No |
| Register | PRINCIPAL |
| Current Location | PUBLICATION AND ISSUE SECTION 2019-04-30 |
| Basis | 66(a) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | No |
| Intent To Use | No |
| Filed ITU | No |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | Yes |
| Current Basis | No |
| No Basis | No |
| Attorney Docket Number | 49827.2042 |
| Law Office Assigned | L40 |
| Employee Name | EISNACH, MICHAEL PATRI |
Timeline
| 2018-02-28 | Application Filed |
| 2019-01-07 | Location: PUBLICATION AND ISSUE SECTION |
| 2019-01-07 | Status: Live/Pending |
| 2019-01-08 | Transaction Date |
| 2019-02-12 | Published |
| 2019-02-12 | Published for Opposition |
| 2019-04-30 | Location: PUBLICATION AND ISSUE SECTION |
| 2019-04-30 | Status: Registered. The registration date is used to determine when post-registration maintenance documents are due. |
| 2019-04-30 | Trademark Registered |
| 2024-04-30 | Maintenance Early File Date |
| 2025-04-30 | Maintenance On Time Date |
| 2025-10-30 | Maintenance Late Fee Date |
Trademark Parties (Applicants & Owners)
| Party: |  Genexine, Inc. |
| Address | (Bio Park,Sampyeong-dong) 4th floor, Bldg B, 700, Daewangpangyo-ro,; Bundang- gu,; Seongnam-si; Gyeonggi-do KOREA, REPUBLIC OF |
| Legal Entity Type | Corporation |
| Legal Entity State | KOREA, REPUBLIC OF |
Documents
 Application | MULTI | 2018-05-24 |
 Drawing | JPEG | 2018-05-24 |
| Madrid Miscellaneous | JPEG | 2018-05-24 |
| Filing Receipt Trademark Application | XML | 2018-06-05 |
| Notation to File | XML | 2018-06-19 |
| Offc Action Outgoing | XML | 2018-06-19 |
| XSearch Search Summary | XML | 2018-06-19 |
| IB-1rst Refusal Note | XML | 2018-06-28 |
| IB-Processed Transaction | XML | 2018-07-12 |
| Change of Address | XML | 2018-12-27 |
| Response to Office Action | XML | 2018-12-27 |
| Amendment and Mail Process Complete | MULTI | 2018-12-28 |
| TRAM Snapshot of App at Pub for Oppostn | MULTI | 2018-12-29 |
| IB-Opposition Notice To | XML | 2019-01-23 |
| Notice of Publication | XML | 2019-01-23 |
| Notification Of Notice of Publication | XML | 2019-01-23 |
| IB-Processed Transaction | XML | 2019-02-07 |
| OG Publication Confirmation | XML | 2019-02-12 |
| Registration Certificate | 2019-04-30 | |
| Change of Address | XML | 2019-05-13 |
| IB-Final Disposal To | XML | 2019-08-24 |
| IB-Processed Transaction | XML | 2019-09-12 |
| IR-Rep Change | XML | 2020-05-28 |
Design Search Codes
| 26.03.21 | Ovals that are completely or partially shaded |
| 260314 | Ovals, three or more; Three or more ovals |
| 260321 | Ovals that are completely or partially shaded |
Attorney of Record
Good, Services, and Codes
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of infectious diseases; Synthetic peptides for pharmaceutical purposes for treating hypertension; Synthetic peptides for pharmaceutical purposes for the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of hormonal disorders and the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of eye diseases and conditions; Synthetic peptides for pharmaceutical purposes for the treatment of multiple sclerosis; Synthetic peptides for pharmaceutical purposes for treating diabetes; Synthetic peptides for pharmaceutical purposes for affecting metabolism; Synthetic peptides for pharmaceutical purposes for regulating the immune system; Synthetic peptides for pharmaceutical purposes for the treatment of viral diseases; Synthetic peptides for pharmaceutical purposes for affecting and treating urogenital organs; Synthetic peptides for pharmaceutical purposes for preventing and treating obesity; Synthetic peptides for pharmaceutical purposes for the treatment of bone diseases; Synthetic peptides for pharmaceutical purposes for wounds; Synthetic peptides for pharmaceutical purposes for activating cellular function; Synthetic peptides for pharmaceutical purposes for affecting digestive organs; Synthetic peptides for pharmaceutical purposes for the treatment of cardiovascular disease; Synthetic peptides for pharmaceutical purposes for treating malignant tumours; Synthetic peptides for pharmaceutical purposes for the treatment and prevention of cancer; Synthetic peptides for pharmaceutical purposes for treatment of viral and infectious diseases, for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of auto-immune diseases
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of infectious diseases; Synthetic peptides for pharmaceutical purposes for treating hypertension; Synthetic peptides for pharmaceutical purposes for the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of hormonal disorders and the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of eye diseases and conditions; Synthetic peptides for pharmaceutical purposes for the treatment of multiple sclerosis; Synthetic peptides for pharmaceutical purposes for treating diabetes; Synthetic peptides for pharmaceutical purposes for affecting metabolism; Synthetic peptides for pharmaceutical purposes for regulating the immune system; Synthetic peptides for pharmaceutical purposes for the treatment of viral diseases; Synthetic peptides for pharmaceutical purposes for affecting and treating urogenital organs; Synthetic peptides for pharmaceutical purposes for preventing and treating obesity; Synthetic peptides for pharmaceutical purposes for the treatment of bone diseases; Synthetic peptides for pharmaceutical purposes for wounds; Synthetic peptides for pharmaceutical purposes for activating cellular function; Synthetic peptides for pharmaceutical purposes for affecting digestive organs; Synthetic peptides for pharmaceutical purposes for the treatment of cardiovascular disease; Synthetic peptides for pharmaceutical purposes for treating malignant tumours; Synthetic peptides for pharmaceutical purposes for the treatment and prevention of cancer; Synthetic peptides for pharmaceutical purposes for treatment of viral and infectious diseases, for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of auto-immune diseases |
| CC0000 | Color is not claimed as a feature of the mark. |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| NEW REPRESENTATIVE AT IB RECEIVED | 2020-05-28 | |
| FINAL DECISION TRANSACTION PROCESSED BY IB | 2019-09-13 | |
| FINAL DISPOSITION PROCESSED | 2019-08-24 | 71529 |
| FINAL DISPOSITION NOTICE SENT TO IB | 2019-08-24 | |
| FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | 2019-07-30 | |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2019-05-13 | |
| REGISTERED-PRINCIPAL REGISTER | 2019-04-30 | |
| PUBLISHED FOR OPPOSITION | 2019-02-12 | |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-02-12 | |
| NOTIFICATION PROCESSED BY IB | 2019-02-08 | |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2019-01-23 | |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2019-01-23 | |
| NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | 2019-01-23 | |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2018-12-28 | |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2018-12-27 | 88889 |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2018-12-27 | |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2018-12-27 | |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2018-12-27 | 88889 |
| REFUSAL PROCESSED BY IB | 2018-07-14 | |
| REFUSAL PROCESSED BY MPU | 2018-06-28 | 73787 |
| NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2018-06-28 | |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2018-06-20 | |
| NON-FINAL ACTION WRITTEN | 2018-06-19 | 91164 |
| ASSIGNED TO EXAMINER | 2018-06-12 | 91164 |
| APPLICATION FILING RECEIPT MAILED | 2018-06-05 | |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-06-01 | |
| SN ASSIGNED FOR SECT 66A APPL FROM IB | 2018-05-24 |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 HYFC TECHNOLOGY 87547399 5568322 Live/Registered |
Genexine, Inc. 2017-07-28 |
 HYFC TECHNOLOGY 79232578 not registered Live/Pending |
Genexine, Inc. 2018-02-28 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 